Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
6/10
|
24.38 | 98.17 | -75.17% | 28.24 | -13.66% |
| P/S |
|
1.64 | 15.43 | -89.34% |
|
|
| P/BV |
|
1.13 | 5.38 | -79.04% |
|
|
| P/FCF |
|
1117.09 | -14.74 | -7677.99% |
|
|
| Ev/Ebitda |
|
12.93 | 18.15 | -28.78% |
|
|
| Ev/S |
|
2.03 | 17.01 | -88.09% |
|
|
| Ev/FCF |
|
1245.13 | 13.46 | 9148.32% |
|
|
| E/P |
|
0.0371 | 0.0234 | 58.38% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
6/10
|
19.16 | -42.13 | -145.49% | 19.4 | -1.23% |
| ROE |
|
5.96 | 2.36 | 152.56% |
|
|
| ROA |
|
2.4 | 2.84 | -15.48% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
6.74 | -55.5 | -112.14% |
|
|
| ROCE |
|
0 | 1.47 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
3/10
|
3.7 | 0.934 | 296.65% | 3.34 | +10.92% |
| Nеt Debt/Ebitda |
|
1.99 | -0.0069 | -28681% |
|
|
| Debt/Ratio |
|
0.2482 | 0.1161 | 113.87% |
|
|
| Debt/Equity |
|
0.9598 | 0.9055 | 6.01% |
|
|
| Debt/Net Income |
|
10.53 | 6.08 | 73.05% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.331 | -100% | 1.07 | -100% |
| Number of years of dividend growth |
|
0 | 1.01 | -100% | ||
| DSI |
|
0.7143 | 0.6649 | 7.43% |
|
|
| Average dividend growth |
|
5.39 | -3.73 | -244.25% |
|
|
| Average percentage for 5 years |
|
1.07 | 1.5 | -28.47% |
|
|
| Average percentage for payments |
|
58.69 | 85.51 | -31.36% |
|
|
| Difference from average difference in sector |
|
-0.331 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
5/10
|
35.5 | 25.7 | 38.13% | ||
| Growth impulse Ebitda in 5 years |
|
-13.61 | 13.87 | -198.13% | ||
| Growth impulse Net Income in 5 years |
|
-24.38 | 253.87 | -109.6% | ||
| Growth impulse FCF in 5 years |
|
-103.6 | 62.85 | -264.84% | ||
| Growth impulse EPS in 5 years |
|
-27.49 | 24.33 | -212.99% |
IP Score
3.84/10
